Skip to main content
SpringerLink
Log in

Endothelin-1 as a Target for Therapeutic Intervention in Prostate Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The endothelins, a family of potentvasoconstricting peptides, have beenimplicated in the pathophysiology ofadvanced prostate cancer. Two endothelinreceptors, ET-A and ET-B are found innormal prostate tissue. Malignant prostatecells are notable for the loss of ET-Breceptors and increased levels ofendothelin-1 [ET-1]; this distortion of theendothelin system may be a significantfactor in the progression of prostatecancer. Proposed roles for endothelin inprostate cancer include growth promotion,apoptosis inhibition, bone formation, andstimulation of nociceptive receptors. ET-1can act alone as a mitogen, but its effectsare greatest as a comitogen with a varietyof growth factors, including basicfibroblast growth factor, insulin-likegrowth factors, and platelet derived growthfactor. Although their exact functions areunclear, ET-1, in conjunction with vascularendothelial growth factor, appears to playa major role in tumor angiogenesis. By avariety of methods, ET-1 alters the balanceof osteoblast and osteoclasts to the favornew bone formation that is characteristicof metastatic disease. Several studiesindicate that the refractory pain ofmetastatic cancer is related to the directnociceptive effects ET-1. These findingssuggest that ET receptors are promisingtherapeutic targets for pharmacologicintervention. Early clinical trialsindicate that the ET-A receptor antagonistused in prostate cancer is reasonably welltolerated with mild but pervasive symptomsrelated to ET-1's vasoconstrictive effects. Results of ongoing clinical trials areeagerly awaited in order to see if thehypothetical promise of ET antagonism willresult in clinical success.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 78: 473–485, 1994

    Google Scholar 

  2. Rubin SA, Levin ER: The endocrinology of vasoactive peptides: synthesis to function. J Clin Endocr Metabol 78: 6–10, 1994

    Google Scholar 

  3. Burkhardt M, Barton M, Shaw SG: Receptor-and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertens 18: 273–279, 2000

    Google Scholar 

  4. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H: Regulation and Intracellular trafficking pathways of the endothelin receptors. J Biol Chem 275: 17596–17604, 2000

    Google Scholar 

  5. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB: The hydrolysis of endothelins by neutral endopeptidase. J Biol Chem 265: 14150–14155, 1990

    Google Scholar 

  6. Battistini B, D'Orleans-Juste P, Sirois P: Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 68: 600–628, 1993

    Google Scholar 

  7. Le Brun G, Aubin P, Soliman H, Ropiquet F, Villette J, Berthon P, Creminon C, Cussenot O, Fiet J: Upregulation of endothelin 1 and its precursor by IL-1β, TNF-α, and TCG-β in the PC3 human prostate cancer cell line. Cyto 11: 157–162, 1999

    Google Scholar 

  8. Goldie RG: Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 26: 145–148, 1999

    Google Scholar 

  9. Lees DM, Pallikaros Z, Corder R: The p55 tumor necrosis factor receptor (CD120a) induces endothelin-1 synthesis in endothelial and epithelial cells. Eur J Pharmacol 390: 89–94, 2000

    Google Scholar 

  10. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46: 328, 1994

    Google Scholar 

  11. Mortensen LH: Endothelin and the clinical and peripheral nervous systems: a decade of endothelin research. Clin Exp Pharmacol Physiol 26: 980–984, 1999

    Google Scholar 

  12. Chiao JW, Moonga BS, Yang YM, Kancheria R, Mittelman A, Wu-Wong JR, Ahmed T: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83: 360–365, 2000

    Google Scholar 

  13. Sullivan ME, Mumtaz FH, Khan MA, Dashwood MR, Thompson CS, Mikhailidis DP, Morgan RJ: Endothelins in the urinary tract. Br J Urology 86: 97–106, 2000

    Google Scholar 

  14. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359: 843–845, 1992

    Google Scholar 

  15. Levy A, Levy N, Wegner S: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 333–400, 1995

    Google Scholar 

  16. Masaki T, Miwa S, Sawamura T, Ninomiya H, Okamoto Y: Subcellular mechanisms of endothelin action in vascular system. Euro J Pharmacol 375: 133–138, 1999

    Google Scholar 

  17. Simonson MS, Herman WH: Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G protein-coupled receptors and pp60c-src. J Biol Chem 268: 9347–9357, 1993

    Google Scholar 

  18. van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ: Receptor-tyrosine-kinase and Gbg-mediated MAP kinase activation by a common signaling pathway. Nature 376: 781–784, 1995

    Google Scholar 

  19. Daub H, Weiss FU, Wallasch U, Ullrich A: Role of transactivation of the EGF receptor in signaling by G-protein coupled receptors. Nature 379: 557–560, 1996

    Google Scholar 

  20. Tsukahara H, Ende H, Magazine H, Bahou W, Goligorsky MS: Molecular and functional characterization of the non-selective ET-B receptor in endothelial cells. J Biol Chem 269: 21778–21785, 1994

    Google Scholar 

  21. Owada A, Tomita K, Terada Y, Sakamoto H, Nonoguchi H, Marumo F: Endothelin (ET)-3 stimulates cyclic guanosine 3',5'-monophosphate production via ETB receptor by producing nitric oxide in isolated rat glomerulus, and in cultured rat mesangial cells. J Clin Invest 93: 556–563, 1994

    Google Scholar 

  22. Warner TD, de Nucci G, Vane JR: Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol 159: 325–326, 1989

    Google Scholar 

  23. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367–1373, 1993

    Google Scholar 

  24. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97: 752–756, 1998

    Google Scholar 

  25. Goligorski MS, Tsukahara H, Magazine H, Anderson TT, Malik AB, Bahou WF: Termination of endothelin signaling: role of nitric oxide. J C Physiol 158: 485–494, 1994

    Google Scholar 

  26. Boulanger C, Luscher TF: Release of endothelin from the porcine aorta: inhibition by endothelin-derived nitric oxide. J Clin Invest 85: 587–590, 1990

    Google Scholar 

  27. Yohn JJ, Smith C, Stevens T, Morelli JG, Shurnas LR, Walchak SJ, Hoffman TA, Kelley KK, Escobedo-Morse A, Yanagisawa M, Kane MA, Samora MR: Autoregulation of endothelin-1 secretion by cultured human keratinocytes via the endothelin B receptor. Biochim Biophys Acta 1224: 454–458, 1994

    Google Scholar 

  28. Fukahiro T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibi M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199: 1491–1465, 1994

    Google Scholar 

  29. Benigni A: Defining the role of endothelin in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens 4: 349–353, 1995

    Google Scholar 

  30. Hartter E, Woloszczuk W: Radioimmunoassay of endothelin. Lancet 1: 909, 1989

    Google Scholar 

  31. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Shin-Ichi S, Jougasaki M, Morichika S, Imura H: Endothelin in human plasma and culture medium or aortic endothelial cells-detection and characterization with radioimmune assay using monoclonal antibody. Biochem Biophys Res Commun 161: 320–326, 1989

    Google Scholar 

  32. Langenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H: Endothelin-1 in the human prostate: tissues levels, source of production and isometric tension studies. J Urol 150: 495–499, 1993

    Google Scholar 

  33. Walden PD, Ittman M, Manaco ME, Lepor H: Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity in prostatic hyperplasia. Prostate 34: 241–250, 1993

    Google Scholar 

  34. Prayer-Galetti T, Rossi GP, Belloni AS, Albertin G, Battanello W, Piovan V, Gardiman M, Pagano F: Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in different zones of the normal prostate. J Urol 157: 2334–2339, 1997

    Google Scholar 

  35. Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H: Localization of endothelin receptors in the human prostate. J Urol 151: 763–766, 1994

    Google Scholar 

  36. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW: Endothelin-1 production and decreased endothelin-B receptor expression in advanced prostate cancer. Cancer Res 56: 663–668, 1996

    Google Scholar 

  37. Filep JG, Foldes-Filep E, Rousseau A, Fournier A, Sirois P, Yano M: Endotheline-1 enhances vascular permeability in the rat heart through the ET-A receptor. Eur J Pharmacol 219: 343–344, 1992

    Google Scholar 

  38. Zouki C, Baron C, Fournier A, Fielep JG: Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET-A receptors and platelet-activating factor. Br J Pharmacol 127: 969–979, 1999

    Google Scholar 

  39. Helset E, Sildnes T, Selkelid R, Konopski ZS: Endothelin-1 stimulates human monocytes in vitro to release TNF-α, interleukin-β and interleukin-6. Med Inflamm 2: 417–422, 1993

    Google Scholar 

  40. Stankova J, D'Orleans-Juste P, Rola-Pleszczynki M: ET-1 induces interleukin-6 gene expression in human umbilical vein endothelial cells: synergistic effect of interleukin-1. Am J Physiol 271: C1073-C1078, 1996

    Google Scholar 

  41. Casey ML, Byrd W, MacDonald PC: Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 74: 223–225, 1992

    Google Scholar 

  42. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS: Methylation of the 5’ CpG island of the endothelin B receptor gene is common in human prostrate cancer. Can Res 57: 35–37, 1997

    Google Scholar 

  43. Zheng H, Pflug BR, Marshall FF, Nelson JB, Brooks JD: Frequent promoter methylation of the endothelin B receptor gene ENDRB in human renal tumors. (abstract) J Urol 161: 137, 1999

    Google Scholar 

  44. Drimal J, Drimal Jr J, Drimal D: Enhanced endothelin ETB receptor down-regulation in human tumor cells. Eur J Pharmacol 396: 19–22, 2000

    Google Scholar 

  45. Kikuchi K, Nakagawa H, Kadono T, Etoh T, Byers HR, Mihm MC, Tamaki K: Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 219: 734–739, 1996

    Google Scholar 

  46. Alanen K, Deng DX, Chakrabarti S: Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology 36: 161–167, 2000

    Google Scholar 

  47. Ahmed SI, Thompson J, Coulson JM, Woll PJ: Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22: 422–432, 2000

    Google Scholar 

  48. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944–949, 1995

    Google Scholar 

  49. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, Burnstock G, Taylor I.: Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 85: 502–506, 1998

    Google Scholar 

  50. Patel KV, Schrey MP: Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts. Br J Cancer 71: 442–447, 1995

    Google Scholar 

  51. Thevarajah S, Udan M, Zheng H, Pflug BR, Nelson JB: Endothelin axis expression in renal cell carcinoma. (abstract) J Urol 161: 137, 1999

    Google Scholar 

  52. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG: Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720–727, 1999

    Google Scholar 

  53. Kanse SM, Wijelath E, Kanthou C, Newman P, Kakkar VV: The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest 72: 376–382, 1995

    Google Scholar 

  54. Ishizaka K, Azuma H, Matsubara O, Kitahara S, Oshima H: Production of endothelin by canine prostatic epithelial cells and its stimulatory effects on their growth. J Androl 50: 559–536, 1999

    Google Scholar 

  55. Daub H, Weiss FU, Wallasch C: Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature 379: 557–560, 1996

    Google Scholar 

  56. Vacca F, Bagnato A, Catt KJ, Tecce R: Transactivation of the epidermal growth factor in endothelin-1 induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60: 5310–5317, 2000

    Google Scholar 

  57. Moraitis S, Langdon SP, Miller WR: Endothelin expression and responsiveness in human ovarian carcinoma cell lines. Eur J Cancer 33: 661–668, 1997

    Google Scholar 

  58. Pagotto U, Arzberger T, Hopfner U, Sauer J, Renner U, Newton CJ, Lange M, Uhl E, Weindl A, Stalla GK: Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumor growth. J Clin Invest 96: 2017–2025, 1995

    Google Scholar 

  59. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ: Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1:1059–1066, 1995

    Google Scholar 

  60. Kitagawa N, Tsutsumi K, Niwa M, Yamaga S, Anda T, Khalid H, Himeno A, Taniyama K, Shibata S: A selective endothelin ETA antagonist, BQ-123, inhibits 125l-endothelin-1 (125l-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells. Cell Mol Neurobiol 14: 105–118, 1994

    Google Scholar 

  61. Moraitis S, Miller WR, Smyth JF, Langdon SP: Paracrine regulation of ovarian cancer by endothelin. Eur J Cancer 35: 1381–1387, 1999

    Google Scholar 

  62. Yang Z, Krasnici N, Luscher T: Endothelin-1 potentiates human smooth muscle cell growth to PDGF. Circulation 100: 5–8, 1999

    Google Scholar 

  63. Fudge K, Bostwick DG, Stearns ME: Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraephithelial neoplasia.Prostate 29: 282–286, 1996

    Google Scholar 

  64. Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxa zole-4-carboxamide. Clin Cancer Res 3: 1167–1177, 1997

    Google Scholar 

  65. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ: Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 76: 1279–1283, 1979

    Google Scholar 

  66. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53: 1102–1106, 1993

    Google Scholar 

  67. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnber M, Bartsch G, Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392–405, 1996

    Google Scholar 

  68. Wu-Wong JR, Chiou WJ, Dickinson R, Opgenorth TJ: Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 328: 733–737, 1997

    Google Scholar 

  69. Okazawa M, Siraki T, Ninomiya H, Kobayashi S, Masaki T: Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 273: 12581–12592, 1998

    Google Scholar 

  70. Kitasjima I, Kawahara K, Nakajima T, Soejima Y, Matsuyama T, Maruyama I: Nitric oxide-mediated apoptosis in murine mastocytoma. Biochem Biophys Res Commun 204: 244–251, 1994

    Google Scholar 

  71. Xie K, Wang Y, Huang S, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang W, Fidler IJ: Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 15: 771–779, 1997

    Google Scholar 

  72. Corasaniti MT, Melino G, Tartaglia RL, Finazzi-Agro A, Nistico G: N-methyl-D-aspartate-induced excessive formation of nitric oxide in CHP100 neuroblastoma cells produces death of BMEL melanoma cells in co-culture. Neuropharmacology 33: 1071–1077, 1994

    Google Scholar 

  73. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J IntMed 181: 1333–1343, 1995

    Google Scholar 

  74. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392–4396, 1995

    Google Scholar 

  75. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature 1: 27–31, 1995

    Google Scholar 

  76. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401, 1993

    Google Scholar 

  77. Ziche M, Morbidelli M, Donnini S, Ledda F: ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol 26: S284–286, 1995

    Google Scholar 

  78. Wren A, Hiley C, Fan TP: Endothelin-3 mediated proliferation of wounded human umbilical vein endothelial cells. Biochem Biophys Res Commun 196: 369–375, 1993

    Google Scholar 

  79. Morbidelli L, Orlando C, Maggi C, Idda F, Zicke M: Proliferation and migration of endothelial cells is promoted by endothelins via activation of ET-B receptors. Am J Physiol 269: H686–695, 1995

    Google Scholar 

  80. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E: Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 26: 269–271, 1999

    Google Scholar 

  81. Pedram A, Razandi M, Hu RM, Levin ER: Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272: 17097–17103, 1997

    Google Scholar 

  82. Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG, Bagnato A: Role of Endothelin-1 in neovascularization of ovarian carcinoma. Amer J Path 157: 1537–1547, 2000

    Google Scholar 

  83. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S: Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45: 216–224, 2000

    Google Scholar 

  84. Salani D, Garagoletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Amer J Path 157: 1703–1711, 2000

    Google Scholar 

  85. Takuwa Y, Ohue Y, Takuwa N: Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra-and intracellular pools in osteoblastic cells. Am J Physiol 257: E797-E803, 1989

    Google Scholar 

  86. Takuwa Y, Masaki T, Yamashita K: The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophy Res Commun 170: 998–1005, 1990

    Google Scholar 

  87. Tatrai A, Foster S, Lakatos P, Shankar G, Stern PH: Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures. Endocrinology 131: 603–607, 1992

    Google Scholar 

  88. Shioide M, Noda M: Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J Cell Biochem 53: 176–180, 1993

    Google Scholar 

  89. Alam ASMT, Gallagher A, Shankar V: Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 130: 3617–3624, 1992

    Google Scholar 

  90. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LWK, Inoue N: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin-A receptor blockade. Urology 53: 1063–1069, 1999

    Google Scholar 

  91. Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L: Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 8: 811–817, 1990

    Google Scholar 

  92. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G: Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 9: 2279–2283, 1998

    Google Scholar 

  93. Yoshizawa T, Kimura S, Kanazawa I, Uchiyama Y, Yanagisawa M, Masaki T: Endothelin localizes in the dorsal horn and acts on the spinal cord neurons: possible involvement of dihydropyridine-sensitive calcium channels and substance P release. Neurosci Lett 102: 179–184, 1989

    Google Scholar 

  94. Dymshitz J, Vasko MR: Endothelin-1 enhances capsaicin-induced peptide release and CGMP accumulation in cultures of rat sensory neurons. Neurosci Lett 167: 128–132, 1994

    Google Scholar 

  95. De-Melo JD, Tonussi CR, D'Orleans-Juste P, Rae GA: Articular nociception by endothelin-1, carrageenan and LPS in naïve and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 77: 261–269, 1998

    Google Scholar 

  96. Raffa RB, Schupsky JJ, Jacoby HI: Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther 276: 647–651, 1996

    Google Scholar 

  97. Piovezan AP, D'Orleans JP, Souza GE, Rae GA: Endothelin-1 induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 129: 961–968, 2000

    Google Scholar 

  98. Yamamoto T, Shimoyama N, Asano H, Mizuguchi T: Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, and endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist. J Pharmacol Exp Ther 27: 156–163, 1994

    Google Scholar 

  99. Benigni A, Remuzzi G: Endothelin antagonists. Lancet 353: 133–138, 1999

    Google Scholar 

  100. Hosoda K, Hammer RE, Richardson JA, Greenstein-Baynash A, Che JC, Giaid A, Yanagisawa M: Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267–1276, 1994

    Google Scholar 

  101. Greenstein-Baynash A, Hosoda K, Giaird A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M: Interaction of endothelin-3 with endothelin receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79: 1277–1285, 1994

    Google Scholar 

  102. Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T, Yazaki Y: Aortic arch malformation and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 96: 293–300, 1995

    Google Scholar 

  103. Carducci MA, Bowling KM, Rogers T, Leahy TL, Nelson JB, Janus TJ, Padley RJ: Endothelin receptor antagonist, ABT-627, for prostate cancer: initial trail results. (abstract) J of Urol 161: 176, 1999

    Google Scholar 

  104. Hewage CM, Jiang L, Parkinson JA, Ramage R, Sadler IH: A linear endothelin-1 analogue: solution structure of ET-1 (Aib1,3,11,15,Nle7) by nuclear magnetic resonance spectroscopy and molecular modeling. Neurochem Intl 35: 35–45, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    E. Scott Kopetz

  2. Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Joel B. Nelson

  3. The Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Michael A. Carducci

Authors
  1. E. Scott Kopetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel B. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. Carducci
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopetz, E.S., Nelson, J.B. & Carducci, M.A. Endothelin-1 as a Target for Therapeutic Intervention in Prostate Cancer. Invest New Drugs 20, 173–182 (2002). https://doi.org/10.1023/A:1015630513908

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015630513908

Search

Navigation